PRL-3在前列腺癌组织中的表达及其意义

Expression and significance of PRL-3 in prostatic carcinoma tissues

目的:研究蛋白酪氨酸磷酸酶PRL-3在前列腺癌及前列腺癌旁增生组织中的表达及其与临床病理特征和生物学行为的关系。方法:采用免疫组织化学S-P法检测60例前列腺石蜡包埋组织中PRL-3的表达情况,其中前列腺增生组织12例,前列腺癌组织48例,均为存档石蜡切片。并应用χ2检验方法分析PRL-3在前列腺癌组织中表达的意义与临床病理特征之间的关系。结果:免疫组化结果显示PRL-3表达定位于前列腺癌组织的细胞浆,癌组织与癌旁增生组织的阳性率为分别为79.2%和25.0%(P<0.05),癌组织中PRL-3的表达明显高于癌旁增生组织。PRL-3表达水平在不同年龄段、有无家族史之间差异无显著性(P>0.05),在不同Gleason评分之间差异有显著性(P<0.05),在不同临床TNM分期之间差异无显著性(P>0.05),在血清PSA浓度≤20ng/mL与PSA浓度>20ng/mL组间差异无显著性(P>0.05)。结论:PRL-3的表达与前列腺癌发生发展机制关系较密切,PRL-3蛋白可作为前列腺癌诊断、治疗及预后判断过程中的一种较有价值的病理学指标。

Objective To study the expression of protein tyrosine phosphatase PRL-3 and to investigate its clinical, pathological and biological behavior implications in prostatic carcinoma. Methods The expression of PRL-3 was examined in 60 paraffin-embedded tissue sections including 48 cases of prostatic carcinoma and 12 cases of benign prostate hyperplasia by immunohistochemical staining. The relationship between PRL-3 expression and clinicopathological features was analyzed by Chi-square test. Results The immunoreactive staining was located in the cytoplasm of prostatic carcinoma. The positive rate of PRL-3 in prostatic carcinoma was 79.2%, which was remarkably higher than that in benign prostate hyperplasia （25.0%,P 〈 0.05）. Furthermore, the positive expression of PRL-3 in prostatic carcinoma samples increased significantly with the increasing of the Gleason score. However, the positive expression of PRL-3 was not different between ages, family medical history, stages or the concentration of prostate-specific antigen in blood serum. Conclusion PRL-3 gene plays an essential role in prostate carcinogenesis and can serve as a marker for the prognosis of prostate cancer.